Drug Trial Radar · NCT05491733
A Bioequivalence Study of APX001 High-load and Low-load Tablets
Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Mar 2, 2021
Primary completion
May 13, 2021
Study completion Jun 23, 2021
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
Conditions
- Invasive Fungal Infections
Interventions
APX001Drug
Low-load oral tablet
APX001ADrug
High-load oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Time to Reach Maximum Observed Plasma Concentration (Tmax)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Area Under the Curve From Time Zero to 24 hours (AUC0-24)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Percentage of Area Under the Curve Extrapolated to Infinity (%AUCextra)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Plasma Decay Half-Life (t1/2)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Apparent Terminal Elimination Rate Constant (λz)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Apparent Total clearance, Calculated as Dose/AUCinf (CL/F)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Apparent Volume of Distribution at Terminal Phase (Vz/F)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Time frame: Baseline through Day 14
- Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline through Day 14
- Number of Participants With Clinically Significant Change in Vital SignsTime frame: Baseline through Day 14
- Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG) AbnormalitiesTime frame: Baseline through Day 14
- Number of Participants With Abnormalities in Physical ExaminationsTime frame: Baseline through Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaceuticals Research Associates, Inc
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.